Posted by Michael Wonder on 18 Dec 2024
Merck announces FDA acceptance of biologics license application for clesrovimab, an investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
17 December 2024 - If approved, clesrovimab has the potential to be available to help address the burden of RSV disease in the US in time for the 2025-26 season
Merck today announced the US FDA has accepted the biologics license application for clesrovimab (MK-1654), the company’s investigational prophylactic long-acting monoclonal antibody designed to protect infants from respiratory syncytial virus disease during their first RSV season.
